title: Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus.
abstract: The oral poliovirus vaccine (OPV) has been effectively used in the control of poliomyelitis and in the eradication of wild polioviruses. Although there are many advantages in using attenuated OPV strains in the campaign to eradicate poliomyelitis, several studies have demonstrated that there are some disadvantages such as (a) excretion by vaccines of OPV-derived polioviruses with genomic modifications known to increase the neurovirulence, (b) appearance of vaccine-associated paralytic poliomyelitis (VAPP) and other adverse effects in vaccinees, (c) occurrence of persistent infections caused by OPV-derived strains in immunodeficient patients with VAPP, (d) transmission of OPV-derived polioviruses to susceptible individuals which develop VAPP, and (e) detection of OPV-derived polioviruses in the environment, which could be a source of infection for humans in the future. Different studies indicate that it is important to consider the possibility of persistent infections and excretion of OPV-derived polioviruses for long periods by humans, and also the survival in the environment of OPV-derived polioviruses excreted by humans, which could be transmitted and circulate in a non-immune population after stopping poliovirus vaccination. The findings reported here may have important implications for global poliomyelitis eradication initiative and indicate that surveillance of OPV-derived strains will also be important in the final step of eradication of poliomyelitis from the planet.
authors.affiliation: Departamento de Virologia, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil. fabian@ioc.fiocruz.br
authors.forename: F
authors.initials: F
authors.lastname: Friedrich
mesh_terms: D000818:Animals; D004777:Environment; D019143:Evolution, Molecular; D016679:Genome, Viral; D014943:Global Health; D006801:Humans; D009422:Nervous System Diseases / Q000150:complications; D010243:Paralysis / Q000821:virology; D011051:Poliomyelitis / Q000150:complications / Q000517:prevention & control* / Q000821:virology; D017955:Poliovirus / Q000235:genetics* / Q000302:isolation & purification / Q000502:physiology; D011055:Poliovirus Vaccine, Oral / Q000235:genetics*; D014779:Virus Replication / Q000235:genetics* / Q000502:physiology
chemical_list: D011055:Poliovirus Vaccine, Oral